{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:47Z","timestamp":1787169827017,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03339-9","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:14:13Z","timestamp":1757412853000},"page":"5600-5611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia\u00a0A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency"],"prefix":"10.1007","volume":"42","author":[{"given":"Thomas G.","family":"Douglas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hatswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"3339_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171:540. https:\/\/doi.org\/10.7326\/M19-1208.","journal-title":"Ann Intern Med"},{"key":"3339_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13998","volume":"26","author":"JM Soucie","year":"2020","unstructured":"Soucie JM, Miller CH, Dupervil B, Le B, Buckner TW. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia. 2020;26:487\u201393. https:\/\/doi.org\/10.1111\/hae.13998.","journal-title":"Haemophilia"},{"key":"3339_CR3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","volume":"104","author":"G Castaman","year":"2019","unstructured":"Castaman G, Matino D. Hemophilia\u00a0A and B: molecular and clinical similarities and differences. Haematologica. 2019;104:1702\u20139. https:\/\/doi.org\/10.3324\/haematol.2019.221093.","journal-title":"Haematologica"},{"issue":"S6","key":"3339_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. Wfh guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"key":"3339_CR5","doi-asserted-by":"publisher","unstructured":"Vietri J, Furlan R, Krishnan S. Patient and parent preferences for characteristics of prophylactic treatment in hemophilia. Patient Prefer Adherence. 2015:1687. https:\/\/doi.org\/10.2147\/PPA.S92520.","DOI":"10.2147\/PPA.S92520"},{"key":"3339_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102615","volume":"8","author":"AD Leavitt","year":"2024","unstructured":"Leavitt AD, Mahlangu J, Raheja P, et al. Efficacy, safety, and quality of life 4\u00a0years after valoctocogene roxaparvovec gene transfer for severe hemophilia\u00a0A in the phase\u00a03 GENEr8-1 trial. Res Pract Thromb Haemost. 2024;8:102615. https:\/\/doi.org\/10.1016\/j.rpth.2024.102615.","journal-title":"Res Pract Thromb Haemost"},{"key":"3339_CR7","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","volume":"22","author":"B Madan","year":"2024","unstructured":"Madan B, Ozelo MC, Raheja P, et al. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia\u00a0A. J Thromb Haemost. 2024;22:1880\u201393. https:\/\/doi.org\/10.1016\/j.jtha.2024.04.001.","journal-title":"J Thromb Haemost"},{"key":"3339_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia\u00a0A. N Engl J Med. 2022;386:1013\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2113708.","journal-title":"N Engl J Med"},{"key":"3339_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia\u00a0A. N Engl J Med. 2023;388:694\u2013705. https:\/\/doi.org\/10.1056\/NEJMoa2211075.","journal-title":"N Engl J Med"},{"key":"3339_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/hae.15071","volume":"30","author":"E Symington","year":"2024","unstructured":"Symington E, Rangarajan S, Lester W, et al. Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7\u00a0years for haemophilia\u00a0A. Haemophilia. 2024;30:1138\u201347. https:\/\/doi.org\/10.1111\/hae.15071.","journal-title":"Haemophilia"},{"key":"3339_CR11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284498","author":"Y Dargaud","year":"2024","unstructured":"Dargaud Y, Leuci A, Ruiz AR, Lacroix-Desmazes S. Efanesoctocog alfa: the renaissance of factor\u00a0VIII replacement therapy. Haematologica. 2024. https:\/\/doi.org\/10.3324\/haematol.2023.284498.","journal-title":"Haematologica"},{"key":"3339_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa2312611","volume":"391","author":"L Malec","year":"2024","unstructured":"Malec L, Peyvandi F, Chan AKC, et al. Efanesoctocog alfa prophylaxis for children with severe hemophilia\u00a0A. N Engl J Med. 2024;391:235\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2312611.","journal-title":"N Engl J Med"},{"key":"3339_CR13","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1111\/jth.15741","volume":"20","author":"M Demers","year":"2022","unstructured":"Demers M, Aleman MM, Kistanova E, Peters R, Salas J, Seth Chhabra E. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor\u00a0VIII. J Thromb Haemost. 2022;20:1674\u201383. https:\/\/doi.org\/10.1111\/jth.15741.","journal-title":"J Thromb Haemost"},{"key":"3339_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia\u00a0A. N Engl J Med. 2023;388:310\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2209226.","journal-title":"N Engl J Med"},{"key":"3339_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12567","volume":"5","author":"E Krumb","year":"2021","unstructured":"Krumb E, Hermans C. Living with a \u201chemophilia-free mind\u201d \u2013 The new ambition of hemophilia care? Res Pract Thromb Haemost. 2021;5:e12567. https:\/\/doi.org\/10.1002\/rth2.12567.","journal-title":"Res Pract Thromb Haemost"},{"key":"3339_CR16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/hae.14807","volume":"29","author":"C Hermans","year":"2023","unstructured":"Hermans C, Pierce GF. Towards achieving a haemophilia-free mind. Haemophilia. 2023;29:951\u20133. https:\/\/doi.org\/10.1111\/hae.14807.","journal-title":"Haemophilia"},{"key":"3339_CR17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137. https:\/\/doi.org\/10.1016\/j.jval.2012.05.004.","journal-title":"Value Health"},{"issue":"3","key":"3339_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/09296174.2013.799918","volume":"20","author":"S Wallis","year":"2013","unstructured":"Wallis S. Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods. J Quantitative Linguistics. 2013;20(3):178\u2013208. https:\/\/doi.org\/10.1080\/09296174.2013.799918","journal-title":"J Quantitative Linguistics"},{"key":"3339_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/21642850.2021.1920416","volume":"9","author":"JA Green","year":"2021","unstructured":"Green JA. Too many zeros and\/or highly skewed? A tutorial on modelling health behaviour as count data with Poisson and negative binomial regression. Health Psychol Behav Med. 2021;9:436\u201355. https:\/\/doi.org\/10.1080\/21642850.2021.1920416.","journal-title":"Health Psychol Behav Med"},{"key":"3339_CR20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28:935\u201345. https:\/\/doi.org\/10.2165\/11538370-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"3339_CR21","unstructured":"R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2023. Available from: https:\/\/www.R-project.org\/"},{"key":"3339_CR22","unstructured":"Young R. Maic: matching-adjusted indirect comparison [Internet]. 2022. Available from: https:\/\/github.com\/heorltd\/maic"},{"key":"3339_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100849","volume":"50","author":"A Di Minno","year":"2021","unstructured":"Di Minno A, Spadarella G, Esposito S, Mathew P, Di Minno G, Mannucci PM. Perspective \u2013 The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia\u00a0A in 2021. Blood Rev. 2021;50:100849. https:\/\/doi.org\/10.1016\/j.blre.2021.100849.","journal-title":"Blood Rev"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03339-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:25Z","timestamp":1762030945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03339-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3339"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03339-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas G. Douglas, Kurt Taylor, and Anthony J. Hatswell are employees of Petauri Evidence. Sandra Santos is an employee and stockholder of BioMarin UK Ltd. David R. Hinds is an employee and stockholder of BioMarin Pharmaceutical Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any newer studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}